Annals of Neurology · 2010 · 88 citations · 16 references
Life SciencesImmunologyPharmacotherapyAdaptive ImmunityImmunopharmacologyImmunotherapyAdaptive Immune ResponsesAntigen RecognitionCell-mediated ImmunityHumoral ImmunityImmune Response To VaccinationMultiple SclerosisAdaptive Immune Responses To Viral InfectionAdaptive Immunity Disease ModelsAntigen-specific Immune ResponseCellular Immune Response AnalysisFingolimod TherapyMultiple Sclerosis TherapySphingosine 1-Phosphate Receptor Modulator TherapyVaccine-induced T Cell Immunity
T cells exit secondary lymphoid organs along a sphingosine1-phosphate (S1P) gradient and, accordingly, are reduced in blood upon fingolimod-mediated S1P-receptor (S1PR)-blockade. Serving as a model of adaptive immunity, we characterized cellular and humoral immune responses to influenza vaccine in fingolimod-treated patients with multiple sclerosis (MS) and in untreated healthy controls. Although the mode of action of fingolimod might predict reduced immunity, vaccine-triggered T cells accumulated normally in blood despite efficient S1PR-blockade. Concentrations of anti-influenza A/B immunoglobulin (Ig)M and IgG also increased similarly in both groups. These results indicate that fingolimod-treated individuals can mount vaccine-specific adaptive immune responses comparable to healthy controls.
16
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Mehrdad Matloubian, Charles G. Lo, Guy Cinamon et al. · Nature · 2004 · 2.5K citations
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Ludwig Kappos, Jack P. Antel, Giancarlo Comi et al. · New England Journal of Medicine · 2006 · 1.1K citations · Full text
Follicular shuttling of marginal zone B cells facilitates antigen transport
Guy Cinamon, Marcus Zachariah, Olivia M Lam et al. · Nature Immunology · 2007 · 531 citations